Torrens M - Search Results

1

MDMA (ecstasy) pharmacokinetics in a CYP2D6 poor metaboliser and in nine CYP2D6 extensive metabolisers.

de la Torre R, Farré M, Mathúna BO, Roset PN, Pizarro N, Segura M, Torrens M, Ortuño J, Pujadas M, Camí J. de la Torre R, et al. Among authors: torrens m. Eur J Clin Pharmacol. 2005 Aug;61(7):551-4. doi: 10.1007/s00228-005-0965-y. Epub 2005 Jul 23. Eur J Clin Pharmacol. 2005. PMID: 16041599 Clinical Trial. No abstract available.

2

Assessment and management of opioid withdrawal symptoms in buprenorphine-dependent subjects.

San L, Camí J, Fernández T, Ollé JM, Peri JM, Torrens M. San L, et al. Among authors: torrens m. Br J Addict. 1992 Jan;87(1):55-62. doi: 10.1111/j.1360-0443.1992.tb01900.x. Br J Addict. 1992. PMID: 1311974 Clinical Trial.

3

Double blind assessment of buprenorphine withdrawal in opiate-addicts.

Sam L, Camí J, Fernandez T, Ollé JM, Peri JM, Torrens M. Sam L, et al. Among authors: torrens m. NIDA Res Monogr. 1990;105:455. NIDA Res Monogr. 1990. PMID: 1876075 No abstract available.

4

The effects of HIV infection on the development of methadone maintenance treatment in Spain.

Torrens M, Camí J. Torrens M, et al. Addiction. 1994 Dec;89(12):1707-8. doi: 10.1111/j.1360-0443.1994.tb03776.x. Addiction. 1994. PMID: 7866257 No abstract available.

5

Flunitrazepam consumption among heroin addicts admitted for in-patient detoxification.

San L, Tato J, Torrens M, Castillo C, Farré M, Camí J. San L, et al. Among authors: torrens m. Drug Alcohol Depend. 1993 May;32(3):281-6. doi: 10.1016/0376-8716(93)90093-6. Drug Alcohol Depend. 1993. PMID: 8102333

6

Consumption of buprenorphine and other drugs among heroin addicts under ambulatory treatment: results from cross-sectional studies in 1988 and 1990.

San L, Torrens M, Castillo C, Porta M, de la Torre R. San L, et al. Among authors: torrens m. Addiction. 1993 Oct;88(10):1341-9. doi: 10.1111/j.1360-0443.1993.tb02020.x. Addiction. 1993. PMID: 8251871

7

Buprenorphine versus heroin dependence: comparison of toxicologic and psychopathologic characteristics.

Torrens M, San L, Camí J. Torrens M, et al. Am J Psychiatry. 1993 May;150(5):822-4. doi: 10.1176/ajp.150.5.822. Am J Psychiatry. 1993. PMID: 8480833

8

Clinical evaluation of the Triage analytic device for drugs-of-abuse testing.

de la Torre R, Domingo-Salvany A, Badia R, Gonzàlez G, McFarlane D, San L, Torrens M. de la Torre R, et al. Among authors: torrens m. Clin Chem. 1996 Sep;42(9):1433-8. Clin Chem. 1996. PMID: 8787700

9

Monitoring patterns of substance use in drug-dependent patients.

San L, Torrens M, Tato J, Castillo C, de la Torre R, Arranz B. San L, et al. Among authors: torrens m. J Subst Abuse Treat. 1998 Sep-Oct;15(5):425-30. doi: 10.1016/s0740-5472(97)00289-4. J Subst Abuse Treat. 1998. PMID: 9750999 Clinical Trial.

10

Plasma methadone concentrations as an indicator of opioid withdrawal symptoms and heroin use in a methadone maintenance program.

Torrens M, Castillo C, San L, del Moral E, González ML, de la Torre R. Torrens M, et al. Drug Alcohol Depend. 1998 Nov 1;52(3):193-200. doi: 10.1016/s0376-8716(98)00096-9. Drug Alcohol Depend. 1998. PMID: 9839145

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

330 results

Search Page

Filters